CN102805863B - 一种人二倍体细胞培养新布尼亚病毒纯化灭活疫苗的制备方法 - Google Patents
一种人二倍体细胞培养新布尼亚病毒纯化灭活疫苗的制备方法 Download PDFInfo
- Publication number
- CN102805863B CN102805863B CN201210121486.5A CN201210121486A CN102805863B CN 102805863 B CN102805863 B CN 102805863B CN 201210121486 A CN201210121486 A CN 201210121486A CN 102805863 B CN102805863 B CN 102805863B
- Authority
- CN
- China
- Prior art keywords
- cell
- virus
- culture
- vaccine
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 241000713112 Orthobunyavirus Species 0.000 title claims abstract description 28
- 210000001840 diploid cell Anatomy 0.000 title claims abstract description 24
- 238000002360 preparation method Methods 0.000 title claims abstract description 17
- 238000000746 purification Methods 0.000 title claims abstract description 13
- 229940031551 inactivated vaccine Drugs 0.000 title claims abstract description 10
- 238000012258 culturing Methods 0.000 title abstract description 3
- 241000700605 Viruses Species 0.000 claims abstract description 86
- 210000004027 cell Anatomy 0.000 claims abstract description 46
- 229960005486 vaccine Drugs 0.000 claims abstract description 29
- 238000011218 seed culture Methods 0.000 claims description 24
- 239000007788 liquid Substances 0.000 claims description 14
- 210000002966 serum Anatomy 0.000 claims description 14
- 230000003612 virological effect Effects 0.000 claims description 11
- 238000000034 method Methods 0.000 claims description 9
- 230000009849 deactivation Effects 0.000 claims description 8
- 201000010099 disease Diseases 0.000 claims description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 8
- 239000005723 virus inoculator Substances 0.000 claims description 8
- 238000003556 assay Methods 0.000 claims description 6
- 239000001963 growth medium Substances 0.000 claims description 6
- VEZXCJBBBCKRPI-UHFFFAOYSA-N beta-propiolactone Chemical compound O=C1CCO1 VEZXCJBBBCKRPI-UHFFFAOYSA-N 0.000 claims description 5
- 229960000380 propiolactone Drugs 0.000 claims description 5
- 239000012930 cell culture fluid Substances 0.000 claims description 4
- 239000000706 filtrate Substances 0.000 claims description 4
- 239000000047 product Substances 0.000 claims description 4
- 238000001179 sorption measurement Methods 0.000 claims description 4
- 239000002435 venom Substances 0.000 claims description 4
- 231100000611 venom Toxicity 0.000 claims description 4
- 210000001048 venom Anatomy 0.000 claims description 4
- 108091006905 Human Serum Albumin Proteins 0.000 claims description 3
- 102000008100 Human Serum Albumin Human genes 0.000 claims description 3
- 108010009736 Protein Hydrolysates Proteins 0.000 claims description 3
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims description 3
- 239000008363 phosphate buffer Substances 0.000 claims description 3
- 231100000614 poison Toxicity 0.000 claims description 3
- 239000002574 poison Substances 0.000 claims description 3
- 239000003223 protective agent Substances 0.000 claims description 3
- 230000006978 adaptation Effects 0.000 claims description 2
- 244000309466 calf Species 0.000 claims description 2
- 239000012531 culture fluid Substances 0.000 claims description 2
- 238000011534 incubation Methods 0.000 claims description 2
- 241001535172 Severe fever with thrombocytopenia virus Species 0.000 abstract description 4
- 230000001954 sterilising effect Effects 0.000 abstract 1
- 231100000033 toxigenic Toxicity 0.000 abstract 1
- 230000001551 toxigenic effect Effects 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 description 12
- 239000002609 medium Substances 0.000 description 8
- 230000036039 immunity Effects 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 210000003501 vero cell Anatomy 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 5
- 238000004113 cell culture Methods 0.000 description 5
- 238000011081 inoculation Methods 0.000 description 4
- 238000012797 qualification Methods 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 230000005847 immunogenicity Effects 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 230000036512 infertility Effects 0.000 description 3
- 238000012423 maintenance Methods 0.000 description 3
- 231100000915 pathological change Toxicity 0.000 description 3
- 230000036285 pathological change Effects 0.000 description 3
- 238000004321 preservation Methods 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 230000001681 protective effect Effects 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 239000002356 single layer Substances 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 241000204031 Mycoplasma Species 0.000 description 2
- 241000150350 Peribunyaviridae Species 0.000 description 2
- 210000000683 abdominal cavity Anatomy 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000003044 adaptive effect Effects 0.000 description 2
- 230000000840 anti-viral effect Effects 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 229940098773 bovine serum albumin Drugs 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 238000000502 dialysis Methods 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 229910052736 halogen Inorganic materials 0.000 description 2
- 150000002367 halogens Chemical class 0.000 description 2
- 238000003306 harvesting Methods 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 230000002779 inactivation Effects 0.000 description 2
- 230000002458 infectious effect Effects 0.000 description 2
- 238000007689 inspection Methods 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 230000003472 neutralizing effect Effects 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 239000002510 pyrogen Substances 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 206010043554 thrombocytopenia Diseases 0.000 description 2
- 231100000820 toxicity test Toxicity 0.000 description 2
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 201000001916 Hypochondriasis Diseases 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 201000000239 Phlebotomus fever Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000013553 cell monolayer Substances 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000005227 gel permeation chromatography Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 230000008383 multiple organ dysfunction Effects 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000005096 rolling process Methods 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000029305 taxis Effects 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
Landscapes
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Description
Claims (3)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201210121486.5A CN102805863B (zh) | 2012-04-24 | 2012-04-24 | 一种人二倍体细胞培养新布尼亚病毒纯化灭活疫苗的制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201210121486.5A CN102805863B (zh) | 2012-04-24 | 2012-04-24 | 一种人二倍体细胞培养新布尼亚病毒纯化灭活疫苗的制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN102805863A CN102805863A (zh) | 2012-12-05 |
CN102805863B true CN102805863B (zh) | 2015-01-07 |
Family
ID=47229846
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201210121486.5A Expired - Fee Related CN102805863B (zh) | 2012-04-24 | 2012-04-24 | 一种人二倍体细胞培养新布尼亚病毒纯化灭活疫苗的制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN102805863B (zh) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113337477A (zh) * | 2021-05-31 | 2021-09-03 | 李家斌 | 一种发热伴血小板减少综合征病毒株的分离方法 |
CN115627255B (zh) * | 2022-12-01 | 2023-04-07 | 天信和(苏州)生物科技有限公司 | 一种采用低血清培养基培养人二倍体细胞的方法 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1248471A (zh) * | 1998-09-23 | 2000-03-29 | 卫生部北京生物制品研究所 | Vero细胞乙型脑炎灭活疫苗及其制备方法 |
-
2012
- 2012-04-24 CN CN201210121486.5A patent/CN102805863B/zh not_active Expired - Fee Related
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1248471A (zh) * | 1998-09-23 | 2000-03-29 | 卫生部北京生物制品研究所 | Vero细胞乙型脑炎灭活疫苗及其制备方法 |
Non-Patent Citations (2)
Title |
---|
Fever with Thrombocytopenia Associated with a Novel Bunyavirus in China;Xue-Jie Yu,et al;《The New England Journal of Medicine》;20110316;1523-1532页 * |
细胞基质的分类;药品审评中心;《疫苗生产用细胞基质的技术审评一般原则》;20051231;1-17 * |
Also Published As
Publication number | Publication date |
---|---|
CN102805863A (zh) | 2012-12-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101869702B (zh) | 以悬浮微载体细胞培养系统产制的疫苗及其方法 | |
CN103083654A (zh) | Celligen310生物反应器制备人二倍体细胞狂犬病疫苗工艺 | |
CN107460156A (zh) | 无血清全悬浮mdck细胞株及其在生产流感病毒中的应用 | |
CN102805862B (zh) | 一种vero细胞培养新布尼亚病毒纯化灭活疫苗的制备方法 | |
CN104338127A (zh) | 一种h9n2亚型禽流感灭活疫苗的生产方法及其制品 | |
CN104928259A (zh) | 一种h9亚型禽流感病毒、灭活疫苗及其制备方法 | |
CN108452298A (zh) | 一种用spf鸡胚细胞生产黄热病减毒活疫苗的工艺 | |
CN102805863B (zh) | 一种人二倍体细胞培养新布尼亚病毒纯化灭活疫苗的制备方法 | |
CN103923885B (zh) | 鸡传染性法氏囊病毒Vero细胞适应株及其应用 | |
CN104164408B (zh) | 抗鸡新城疫、传染性支气管炎和禽流感疫苗组合物及制备 | |
CN102049043A (zh) | 一种牛传染性鼻气管炎疫苗及其制备方法 | |
CN103127497B (zh) | 猪圆环病毒2型、肺炎支原体二联灭活疫苗及其制备方法 | |
CN109395099B (zh) | 一种提高结核菌素bcg-ppd皮试诊断试剂稳定性的方法 | |
CN103751772A (zh) | 一种制备f基因型腮腺炎减毒活疫苗的方法 | |
CN103864931B (zh) | 一种伪狂犬病标准阳性血清的制备及其冻干保存方法 | |
CN106474467A (zh) | 伪狂犬病灭活疫苗及其制备方法 | |
CN102600465A (zh) | 鸡新城疫活疫苗的生产方法及其产品 | |
CN112717128B (zh) | 一种预防手足口病的联合疫苗及其制备方法和应用 | |
CN101380470B (zh) | 一种猪细小病毒活疫苗 | |
CN102114243B (zh) | 流行性感冒原代地鼠肾细胞多价疫苗的制备方法 | |
CN111551747A (zh) | 基于抗体检测用兔检验猪塞内卡病毒病灭活疫苗效力的方法 | |
CN116615234A (zh) | 一种预防手足口病的联合疫苗及其制备方法和应用 | |
CN103160474B (zh) | 肠道病毒71型病毒株、疫苗、动物模型建立方法 | |
CN106085947B (zh) | Mdck克隆细胞株及其应用 | |
CN111057683A (zh) | 一种鸡胚接种用病毒稀释液及其制备方法和应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: WUXI XINLIANXIN BIOMEDICINE TECHNOLOGY CO., LTD. Free format text: FORMER OWNER: WAN LIMING Effective date: 20150803 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20150803 Address after: 214142 Jiangsu New District of Wuxi City Linghu Road No. 97, building B-2, Inc. Patentee after: WUXI SINOSBIO BIOMEDICAL TECHNOLOGY CO.,LTD. Address before: 214121, Jiangsu Province, Wuxi Binhu District Vanke City Garden District 282-1702, room two Patentee before: Wan Liming |
|
DD01 | Delivery of document by public notice |
Addressee: WUXI SINOSBIO BIOMEDICAL TECHNOLOGY CO.,LTD. Document name: Notification of Passing Examination on Formalities |
|
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20150107 |
|
CF01 | Termination of patent right due to non-payment of annual fee |